INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

25.03.25 15:00 Uhr

Werte in diesem Artikel

NEW YORK, March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On March 18, 2025, Sarepta issued a press release disclosing the death of "a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS", Sarepta's Duchenne muscular dystrophy drug, "having suffered acute liver failure." 

On this news, Sarepta's stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

 CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sarepta-therapeutics-inc---srpt-302410142.html

SOURCE Pomerantz LLP

In eigener Sache

Übrigens: Sarepta Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Sarepta Therapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sarepta Therapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sarepta Therapeutics Inc.

Wer­bung

Analysen zu Sarepta Therapeutics Inc.

DatumRatingAnalyst
21.08.2019Sarepta Therapeutics BuyNeedham & Company, LLC
01.10.2018Sarepta Therapeutics OverweightCantor Fitzgerald
21.06.2018Sarepta Therapeutics OutperformRobert W. Baird & Co. Incorporated
20.06.2018Sarepta Therapeutics BuyNeedham & Company, LLC
19.06.2018Sarepta Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
21.08.2019Sarepta Therapeutics BuyNeedham & Company, LLC
01.10.2018Sarepta Therapeutics OverweightCantor Fitzgerald
21.06.2018Sarepta Therapeutics OutperformRobert W. Baird & Co. Incorporated
20.06.2018Sarepta Therapeutics BuyNeedham & Company, LLC
19.06.2018Sarepta Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
26.04.2016Sarepta Therapeutics Sector PerformRBC Capital Markets
22.04.2016Sarepta Therapeutics Sector PerformRBC Capital Markets
20.05.2015Sarepta Therapeutics Sector PerformRBC Capital Markets
23.01.2015Sarepta Therapeutics Sector PerformRBC Capital Markets
28.10.2014Sarepta Therapeutics NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
26.04.2016Sarepta Therapeutics ReduceSunTrust Robinson Humphrey, Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sarepta Therapeutics Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen